Open an account

Viridian Therapeutics

VRDN · NASDAQ

$22.43+$1.63 (+7.84%)TodayMarket closed ·
Prev close $20.80

About VRDN

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. The company is headquartered in Waltham, Massachusetts and currently employs 252 full-time employees. The company went IPO on 2014-06-18. The firm is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The firm is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of veligrotug in patients with active and chronic TED. The company is also conducting two global Phase 3 clinical trials, REVEAL-1 and REVEAL-2, to evaluate the efficacy and safety of VRDN-003 in patients. Its advanced program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Employees
252
Headquarters
Waltham, Massachusetts
Listed
Jun 18, 2014
Sector
Health Care
Industry
Biotechnology
Website
viridiantherapeutics.com

VRDN key statistics

Market cap
2.16B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
2.16M
Volume
1.97M
Open price
$21.10
High today
$22.68
Low today
$20.85
52 Week high
$34.29
52 Week low
$13.18

Viridian Therapeutics (VRDN) at a glance

As of Oct 20, 2026, Viridian Therapeutics (VRDN) shares are priced at $22.43, giving the company a market cap of 2.16B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $20.85 and $22.68. The current price is 7.6% above the day's low and 1.1% below its high.

Volume so far is 1.97M shares, in line with the average of 2.16M shares a day.

Over the past year Viridian Therapeutics has ranged from $13.18 to $34.29, and now sits 44% of the way up that range.

Viridian Therapeutics met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$1.05 per share against an estimate of -$1.05.

The average analyst price target is $36.92, 64.6% above the current price, from 12 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 12 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 17 analystsAvg $36.92
Low
$22.22
Now
$22.43
High
$52.50

VRDN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 18.3% on average.

  1. Q3 FY24: reported -$1.15 per share against an estimate of -$1.08
  2. Q4 FY24: reported -$1.00 per share against an estimate of -$1.06
  3. Q1 FY25: reported -$0.87 per share against an estimate of -$0.9864
  4. Q2 FY25: reported -$1.00 per share against an estimate of -$1.03
  5. Q3 FY25: reported -$0.34 per share against an estimate of -$1.10
  6. Q4 FY25: reported -$1.08 per share against an estimate of -$1.09
  7. Q1 FY26: reported -$0.90 per share against an estimate of -$1.12
  8. Q2 FY26: reported -$1.05 per share against an estimate of -$1.05

VRDN news

  • Press releaseBusiness Wire

    Viridian Therapeutics to Report Third Quarter 2026 Financial Results on November 4, 2026

  • Vandana Singh

    Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapy

  • Press releaseBusiness Wire

    Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

  • Press releaseGlobe Newswire

    4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

  • Vandana Singh

    Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

  • Rishabh Mishra

    Stock Market Today: Nasdaq, Dow S&P 500 Futures Jump As Trump Admin Says US, Iran Will 'Stand Down' For Now— Verizon, HP, Universe Pharmaceuticals In Focus (UPDATED)

  • Press releaseBusiness Wire

    Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa™ (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

  • Press releaseBusiness Wire

    Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Similar companies

Companies in the same industry as Viridian Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.